Surrozen, Inc./DE Gain (Loss) on Termination of Lease
Surrozen, Inc./DE (SRZN) reported Gain (Loss) on Termination of Lease of $400.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2025-08-08
- Surrozen, Inc./DE gain (loss) on termination of lease for the quarter ending 2025-03-31 was $400.00K.
- Surrozen, Inc./DE gain (loss) on termination of lease for fiscal 2024 was $400.00K.
| Period end | Gain (Loss) on Termination of Lease 3 month | Gain (Loss) on Termination of Lease 6 month | Gain (Loss) on Termination of Lease 12 month |
|---|---|---|---|
| 2025-06-30 | $400.00K 10-Q · filed 2025-08-08 | ||
| 2025-03-31 | $400.00K 10-Q · filed 2025-05-09 | ||
| 2024-12-31 | $400.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |